Lygenesis
Pittsburgh, US · Delaware corporation · 1 known investors
LyGenesis is a clinical-stage cell therapy company that uses a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. Its allogeneic cell therapies target diseases including end stage liver disease, end stage renal disease, Type 1 diabetes, and aging of the thymus.
Founders & leadership
EL
Eric LagasseCo-founder
MH
Michael HuffordCo-founder
PF
Paulo FontesCo-founder
EL
Eric LegasseCo-founder
GB
Gregory BaileyNamed on SEC filing
Board
JM
James MellonBoard director
SF
Steve FelsteadBoard director
JB
Investors · 1
Reported raises · per SEC filings
Form D private placements$25.8M disclosed across 4 rounds · 2018–2023
▶$17.8MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
▶$17.8MraisedOct 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James MellonDirector
- Steve FelsteadDirector
- Eric LagasseExecutive Officer, Director
- Justin BriggsDirector
- Michael HuffordExecutive Officer, Director, Promoter
- Offering amount
- $20M
- Amount sold
- $17.8M
- Proceeds to insiders
- $1.6M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedDec 2020 · 7 investors · BiotechnologyRule 506(b)
▶$1.9MraisedDec 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HuffordExecutive Officer, Director, Promoter
- Eric LagasseExecutive Officer
- Paulo FontesExecutive Officer
- James MellonDirector
- Offering amount
- $20.5M
- Amount sold
- $1.9M
- Proceeds to insiders
- $1.1M
- First sale
- Dec 2020
- Incorporated
- Corporation, De, 2017
- Federal exemptions
- 06b
▶$4MraisedOct 2019 · 2 investors · BiotechnologyRule 506(b)
▶$4MraisedOct 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric LegasseExecutive Officer, Promoter
- Paulo FontesExecutive Officer, Promoter
- Michael HuffordExecutive Officer, Director, Promoter
- Gregory BaileyDirector
- Offering amount
- $4M
- Amount sold
- $4M
- Proceeds to insiders
- $895K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.2MraisedMay 2018 · 2 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMay 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paulo FontesExecutive Officer, Promoter
- Eric LegasseExecutive Officer, Promoter
- Gregory BaileyDirector
- Michael HuffordExecutive Officer, Director, Promoter
- Offering amount
- $3.2M
- Amount sold
- $2.2M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapOrgenesis11 shared keywordsOrgenesis operates the POCare Platform for developing, scaling, and commercializing advanced cell and gene therapies delivered at the point of care. It works with academia, research institutes, and hospitals to bring these therapies to patients globally.
eGenesis9 shared keywordseGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
Organogenesis6 shared keywordsOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Genesis Molecular AI5 shared keywordsGenesis develops GEMS, an AI platform for drug discovery that identifies and optimizes drug candidates. The company partners with pharmaceutical firms like Incyte and Gilead to accelerate the identification and optimization of new drugs.
Amogy3 shared keywordsAmogy develops patented ammonia cracking technology that converts ammonia into electric power for hydrogen fuel cells and engines, targeting decarbonization of heavy industries including transportation and maritime. The company offers modular ammonia-to-power systems and high-efficiency catalysts as alternatives to diesel and hydrogen fuel solutions.
Companies competing with Lygenesis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Lygenesis do?
- LyGenesis is a clinical-stage cell therapy company that uses a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. Its allogeneic cell therapies target diseases including end stage liver disease, end stage renal disease, Type 1 diabetes, and aging of the thymus.
- Who founded Lygenesis?
- Lygenesis was founded by Eric Lagasse, Michael Hufford, Paulo Fontes, Eric Legasse.
- Who are Lygenesis's investors?
- Lygenesis's investors include Prime Movers Lab.
- How much funding has Lygenesis raised?
- Lygenesis has disclosed $25.8M raised across 4 rounds.
- Where is Lygenesis headquartered?
- Lygenesis is headquartered in Pittsburgh, US.